ASCO 2019 Conference Review - focus on Prostate Cancer, reviewed by Associate Professor Arun Azad

In this review:

TITAN shows apalutamide prolongs life in patients with mCSPC
ENZAMET shows enzalutamide improves overall survival in mHSPC
ARCHES finds a delayed time to progression with ENZ/ ADT treatment in mHSPC
Bone protecting agents essential for fracture prevention during ENZ/Ra-223 therapy
TOPARP-B finds olaparib shows efficacy in men with DNA damage repair alterations
PSMA heterogeneity and DNA repair defects in prostate cancer
Cabazitaxel versus AR-targeted therapy in patients with poor prognosis mCRPC
No benefit to the addition of metformin to docetaxel treatment in mCRPC
Alliance shows no improved survival to combination ENZ/AAP
ENZ/LY3023414 delays disease progression in AR-V7 negative mCRCP

Please login below to download this issue (PDF)

Subscribe